Synakis is developing novel biomaterial-based treatments for ocular conditions. Created in https://BioRender.com.
Synakis is a pre-clinical biotech startup developing novel biomaterial-based treatments for ocular injuries and diseases, including retinal detachment and glaucoma. Our mission is to restore vision and improve the lives of patients suffering from these conditions.
Synakis’ core technology, SNK-125, is a novel hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous substitute for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Synakis Welcomed into Ontario Genomics’ BioCreate Program, Securing $150,000 in Funding
March 12, 2026
Synakis has been selected as one of eight biotech companies to join Cohort 6/7 of the BioCreate Program. The 18-month accelerator program provides $150,000 in seed funding.
Synakis Engages Community at Ophthalmic Drug Delivery Summit, Glaucoma 360, and OBIO Investment Summit
February 3, 2026
Synakis CEO Thierry Nivaggioli presented at the Ophthalmic Drug Delivery Summit and Glaucoma 360 New Horizons Forum in San Francisco, CA, while Director of R&D Adam Forman represented Synakis at the OBIO Investment Summit in Toronto, ON.
Synakis CEO Thierry Nivaggioli presenting at the Glaucoma 360 New Horizons Forum.
Upcoming Events
Want to meet our team and learn more about Synakis? Meet us at these upcoming events: